AAV Gene Therapy for Hypertrophic Cardiomyopathy

USPTO published patent application US20260091139A1 disclosing AAV gene therapy vectors and methods for treating hypertrophic cardiomyopathy by addressing reduced levels of functional cardiac myosin binding protein C. The application covers gene therapy compositions and treatment methods with CPC classifications including A61K 48/0058 and C12N 15/86. The 2026 publication date follows the standard 18-month publication window from the September 2023 filing date.

This is a patent application publication, not a regulatory rule or enforcement action. It creates no compliance obligations, deadlines, or penalties. Pharmaceutical companies, biotech firms, and healthcare researchers developing gene therapies for cardiac conditions may wish to review the claims for potential licensing opportunities or freedom-to-operate considerations. No action is required for regulatory compliance purposes.